Renovaro Inc., an AI cancer company, regains Nasdaq compliance after stock price recovery.

Renovaro Inc., a company focusing on cancer diagnostics and therapeutics using AI, has regained compliance with Nasdaq's minimum bid price requirement. The company had previously received a notice in September that its stock price fell below $1.00 per share, which is required for listing on the Nasdaq. Renovaro now meets the listing criteria, ensuring its shares can continue trading on the market.

3 months ago
6 Articles

Further Reading